BF-derm1

Drug Profile

BF-derm1

Alternative Names: BF-derm 1

Latest Information Update: 20 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biofrontera AG
  • Class Skin disorder therapies
  • Mechanism of Action Histidine decarboxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Urticaria

Highest Development Phases

  • Phase II Urticaria

Most Recent Events

  • 20 Aug 2015 BF-derm1 is still in phase-II development for Urticaria in Europe
  • 27 Jul 2009 BF-derm1 is available for licensing (http://www.biofrontera.com)
  • 27 Jul 2009 Efficacy and adverse events data from a phase II trial in Urticaria released by Biofrontera
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top